Search

Your search keyword '"Samur M"' showing total 148 results
Start Over Author "Samur M"
148 results on '"Samur M"'

4. P881: CDK7 CONTRIBUTES TO METABOLIC REPROGRAMMING IN MM CELLS THROUGH C-MYC MEDIATED TRANSCRIPTIONAL CONTROL OF GLYCOLYTIC GENES

Author

Yao, Y., primary, Fong Ng, J., additional, Park, W. D., additional, Gramegna, D., additional, Samur, A., additional, Samur, M., additional, Morelli, E., additional, Chesi, M., additional, Mitsiades, C., additional, Anderson, K. C., additional, Lin, C., additional, Munshi, N., additional, and Fulciniti, M., additional

Published
2022
Full Text
View/download PDF

5. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

Author

Munshi, N.C. Avet-Loiseau, H. Anderson, K.C. Neri, P. Paiva, B. Samur, M. Dimopoulos, M. Kulakova, M. Lam, A. Hashim, M. He, J. Heeg, B. Ukropec, J. Vermeulen, J. Cote, S. Bahlis, N.

Subjects
body regions, hemic and lymphatic diseases
Abstract

The prognostic value of minimal residual disease (MRD) for progression-free survival (PFS) and overall survival (OS) was evaluated in a large cohort of patients with multiple myeloma (MM) using a systematic literature review and meta-analysis. Medline and EMBASE databases were searched for articles published up to 8 June 2019, with no date limit on the indexed database. Clinical end points stratified by MRD status (positive or negative) were extracted, including hazard ratios (HRs) on PFS and OS, P values, and confidence intervals (CIs). HRs were estimated based on reconstructed patient-level data from published Kaplan- Meier curves. Forty-four eligible studies with PFS data from 8098 patients, and 23 studies with OS data from 4297 patients were identified to assess the association between MRD status and survival outcomes. Compared with MRD positivity, achieving MRD negativity improved PFS (HR, 0.33; 95% CI, 0.29-0.37; P < .001) and OS (HR, 0.45; 95% CI, 0.39-0.51; P < .001). MRD negativity was associated with significantly improved survival outcomes regardless of disease setting (newly diagnosed or relapsed/refractory MM), MRD sensitivity thresholds, cytogenetic risk, method of MRD assessment, depth of clinical response at the time of MRD measurement, and MRD assessment premaintenance and 12 months after start of maintenance therapy. The strong prognostic value of MRD negativity and its association with favorable outcomes in various disease and treatment settings sets the stage to adopt MRD as a treatment end point, including development of therapeutic strategies. This large meta-analysis confirms the utility of MRD as a relevant surrogate for PFS and OS in MM. © 2020 by The American Society of Hematology.

Published
2020

11. PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE-CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA

Author

Prabhala, R., primary, Samur, M., additional, Talluri, S., additional, Stekla, M., additional, Acharya, S., additional, Yenumula, C., additional, Nanjappa, P., additional, Lopez, M., additional, Buonopane, M., additional, Heubeck, A., additional, Fulciniti, M., additional, Szalat, R., additional, Lazo-Kallanian, S., additional, Hong, K., additional, Peluso, T., additional, Daley, J., additional, Biyukov, T., additional, Rocafiguera, A. Oriol, additional, Beksac, M., additional, Dimopoulos, M., additional, Hussain, M., additional, Pierceall, W., additional, Richardson, P., additional, Anderson, K., additional, Thakurta, A., additional, Avet-Loiseau, H., additional, and Munshi, N., additional

Published
2019
Full Text
View/download PDF

12. S119 THE ROLE OF RECURRENT SOMATIC ALTERATIONS IN THE NON-CODING GENOME WITH FUNCTIONAL IMPLICATIONS IN MM

Author

Samur, M., primary, Szalat, R., additional, Aktas Samur, A., additional, Fulciniti, M., additional, Lopez, M., additional, Shammas, M., additional, Richardson, P., additional, Magrangeas, F., additional, Minvielle, S., additional, Moreau, P., additional, Attal, M., additional, Thakurta, A., additional, Anderson, K., additional, Parmigiani, G., additional, Avet-Loiseau, H., additional, and Munshi, N., additional

Published
2019
Full Text
View/download PDF

15. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

Author

Maura, F, primary, Petljak, M, additional, Lionetti, M, additional, Cifola, I, additional, Liang, W, additional, Pinatel, E, additional, Alexandrov, L B, additional, Fullam, A, additional, Martincorena, I, additional, Dawson, K J, additional, Angelopoulos, N, additional, Samur, M K, additional, Szalat, R, additional, Zamora, J, additional, Tarpey, P, additional, Davies, H, additional, Corradini, P, additional, Anderson, K C, additional, Minvielle, S, additional, Neri, A, additional, Avet-Loiseau, H, additional, Keats, J, additional, Campbell, P J, additional, Munshi, N C, additional, and Bolli, N, additional

Published
2017
Full Text
View/download PDF

16. Expressed fusion gene landscape and its impact in multiple myeloma

Author

Cleynen, A., primary, Szalat, R., additional, Kemal Samur, M., additional, Robiou du Pont, S., additional, Buisson, L., additional, Boyle, E., additional, Chretien, M. L., additional, Anderson, K., additional, Minvielle, S., additional, Moreau, P., additional, Attal, M., additional, Parmigiani, G., additional, Corre, J., additional, Munshi, N., additional, and Avet-Loiseau, H., additional

Published
2017
Full Text
View/download PDF

17. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma

Author

Gullà, A, primary, Hideshima, T, additional, Bianchi, G, additional, Fulciniti, M, additional, Kemal Samur, M, additional, Qi, J, additional, Tai, Y-T, additional, Harada, T, additional, Morelli, E, additional, Amodio, N, additional, Carrasco, R, additional, Tagliaferri, P, additional, Munshi, N C, additional, Tassone, P, additional, and Anderson, K C, additional

Published
2017
Full Text
View/download PDF

18. A new multiple myeloma classification system that correlates to disease stage and prognosis:Indication of reversible phenotypic plasticity as a hallmark

Author

Johnsen, Hans Erik, Bødker, Julie Støve, Schmitz, Alexander, Larsen, Steffen Falgreen, Perez-Andres, M., Samur, M. K., Davies, F., Pawlyn, C., Kaiser, M., Johnson, D., Bertsch, U., Broijl, A., van Duin, M., Shah, R., Kjeldsen, Malene Krag, Bergkvist, Kim Steve, Bilgrau, Anders Ellern, Johansen, Preben, El-Galaly, Tarec, Samworth, R., Sonneveld, P., Goldschmidt, H., Morgan, G. J., Orfao, A., Munshi, N, Dybkær, Karen, and Bøgsted, Martin

Published
2016

19. 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors

Author

Gu, Y, primary, Xu, K, additional, Torre, C, additional, Samur, M, additional, Barwick, B G, additional, Rupji, M, additional, Arora, J, additional, Neri, P, additional, Kaufman, J, additional, Nooka, A, additional, Bernal-Mizrachi, L, additional, Vertino, P, additional, Sun, S-Y, additional, Chen, J, additional, Munshi, N, additional, Fu, H, additional, Kowalski, J, additional, Boise, L H, additional, and Lonial, S, additional

Published
2017
Full Text
View/download PDF

20. Nucleotide excision repair is a potential therapeutic target in multiple myeloma

Author

Szalat, R, primary, Samur, M K, additional, Fulciniti, M, additional, Lopez, M, additional, Nanjappa, P, additional, Cleynen, A, additional, Wen, K, additional, Kumar, S, additional, Perini, T, additional, Calkins, A S, additional, Reznichenko, E, additional, Chauhan, D, additional, Tai, Y-T, additional, Shammas, M A, additional, Anderson, K C, additional, Fermand, J-P, additional, Arnulf, B, additional, Avet-Loiseau, H, additional, Lazaro, J-B, additional, and Munshi, N C, additional

Published
2017
Full Text
View/download PDF

21. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth

Author

Fulciniti, M, primary, Amodio, N, additional, Bandi, R L, additional, Cagnetta, A, additional, Samur, M K, additional, Acharya, C, additional, Prabhala, R, additional, D'Aquila, P, additional, Bellizzi, D, additional, Passarino, G, additional, Adamia, S, additional, Neri, A, additional, Hunter, Z R, additional, Treon, S P, additional, Anderson, K C, additional, Tassone, P, additional, and Munshi, N C, additional

Published
2016
Full Text
View/download PDF

22. Factors related to truth-telling practice of physicians treating

Author

Ozdogan, M, Samur, M, Artac, M, Yildiz, M, Savas, B, and Bozcuk, HS

Subjects
education, humanities
Abstract

Background: In the practice of oncology, effective communication between physician and patient is very important. Although many studies have indicated that a large majority of physicians, especially from Western countries, tell the truth about diagnosis and prognosis, little is known about attitudes of physicians in Turkey toward truth-telling. Objective: In this study, we tried to determine the truth-telling practice of physicians and explore potential related factors with a self-reported questionnaire. Design: Using a questionnaire, 131 cancer specialists were interviewed during the 15th National Oncology Meeting in April 2003. Results: The percentage of physicians who never, rarely, generally, and always prefer truth-telling about a cancer diagnosis were 9%, 39%, 45%, and 7%, respectively. In univariate logistic regression analysis for the truth-telling practice, significant variables included "'do not tell" requests from family, experiences from medical training and clinical practice, and medical specialty. In the multivariate analysis, "'do not tell" requests from relatives and medical training factors retained their significance. Conclusion: Professional training in breaking bad news is important and is associated with the self-reported truth-telling practices of physicians. C1 Akdeniz Univ, Fac Med, Sch Med, Dept Med Oncol, TR-07070 Arapsuyu, Antalya, Turkey. Pamukkale Univ, Sch Med, Dept Med Oncol, Denizli, Turkey.

Published
2006

23. multidrug resistance protein-1 dependent way: An in vitro study

Author

Yildiz, M, Celik-Ozenci, C, Akan, S, Akan, I, Sati, L, Demir, R, Savas, B, Ozben, T, Samur, M, Ozdogan, M, Artac, M, and Bozcuk, H

Subjects
apoptosis, zoledronic acid, TUNEL, multidrug resistance, vinblastine
Abstract

We have explored the action of zoledronic acid, which has an apoptotic effect and is used as an agent for treating skeletal metastases and osteoporosis, in the presence of vinblastine, and whether this effect is associated with MRP-1 (multidrug resistance protein-1) expression. HEK (human embryonic kidney) 293 cells were transfected to form the multidrug resistant cell line designated 293MRP (MRP-1 expressing HEK293 cells). Both lines were treated with varying concentrations of vinblastine and zoledronic acid. Apoptosis was determined by the TUNEL (deoxyuridine triphosphate nick end-labeling) method. The type of treatment, MRP-1 expression status, and the type of treatment with respect to MRP-1 expression status significantly affected (P < 0.001) the degree of apoptosis. The largest increase in cytotoxicity was noted in HEK293 cells, when 100 mu mol zoledronic acid was added to 4 mu g/ml vinblastine (an increment of 80.3%, P < 0.001). This preliminary work shows that zoledronic acid acts synergistically with vinblastine to induce apoptosis in an MRP-1 dependent way. (C) 2005 Published by Elsevier Ltd on behalf of International Federation for Cell Biology. C1 Akdeniz Univ, Fac Med, Dept Med Oncol, TR-07070 Antalya, Turkey. Pamukkale Univ, Fac Med, Dept Med Oncol, Denizli, Turkey. Akdeniz Univ, Fac Med, Dept Histol & Embryol, TR-07070 Antalya, Turkey. Akdeniz Univ, Fac Med, Dept Biochem, TR-07070 Antalya, Turkey.

Published
2006

24. Zoledronic acid is synergic with vinblastine to induce apoptosis in a

Author

Yildiz, M, Celik-Ozenci, C, Akan, S, Akan, I, Sati, L, Demir, R, Savas, B, Ozben, T, Samur, M, Ozdogan, M, Artac, M, and Bozcuk, H

Subjects
stomatognathic system, apoptosis, zoledronic acid, TUNEL, multidrug resistance, vinblastine
Abstract

We have explored the action of zoledronic acid, which has an apoptotic effect and is used as an agent for treating skeletal metastases and osteoporosis, in the presence of vinblastine, and whether this effect is associated with MRP-1 (multidrug resistance protein-1) expression. HEK (human embryonic kidney) 293 cells were transfected to form the multidrug resistant cell line designated 293MRP (MRP-1 expressing HEK293 cells). Both lines were treated with varying concentrations of vinblastine and zoledronic acid. Apoptosis was determined by the TUNEL (deoxyuridine triphosphate nick end-labeling) method. The type of treatment, MRP-1 expression status, and the type of treatment with respect to MRP-1 expression status significantly affected (P < 0.001) the degree of apoptosis. The largest increase in cytotoxicity was noted in HEK293 cells, when 100 mu mol zoledronic acid was added to 4 mu g/ml vinblastine (an increment of 80.3%, P < 0.001). This preliminary work shows that zoledronic acid acts synergistically with vinblastine to induce apoptosis in an MRP-1 dependent way. (C) 2005 Published by Elsevier Ltd on behalf of International Federation for Cell Biology.

Published
2006

25. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma

Author

Gullà, A, Hideshima, T, Bianchi, G, Fulciniti, M, Kemal Samur, M, Qi, J, Tai, Y-T, Harada, T, Morelli, E, Amodio, N, Carrasco, R, Tagliaferri, P, Munshi, N C, Tassone, P, and Anderson, K C

Abstract

Arginine methyltransferases critically regulate cellular homeostasis by modulating the functional outcome of their substrates. The protein arginine methyltransferase 5 (PRMT5) is an enzyme involved in growth and survival pathways promoting tumorigenesis. However, little is known about the biologic function of PRMT5 and its therapeutic potential in multiple myeloma (MM). In the present study, we identified and validated PRMT5 as a new therapeutic target in MM. PRMT5 is overexpressed in patient MM cells and associated with decreased progression-free survival and overall survival. Either genetic knockdown or pharmacological inhibition of PRMT5 with the inhibitor EPZ015666 significantly inhibited growth of both cell lines and patient MM cells. Furthermore, PRMT5 inhibition abrogated NF-κB signaling. Interestingly, mass spectrometry identified a tripartite motif-containing protein 21 TRIM21 as a new PRMT5-partner, and we delineated a TRIM21-dependent mechanism of NF-κB inhibition. Importantly, oral administration of EPZ015666 significantly decreased MM growth in a humanized murine model of MM. These data both demonstrate the oncogenic role and prognostic relevance of PRMT5 in MM pathogenesis, and provide the rationale for novel therapies targeting PRMT5 to improve patient outcome.

Published
2018
Full Text
View/download PDF

26. Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

Author

Maura, F, Petljak, M, Lionetti, M, Cifola, I, Liang, W, Pinatel, E, Alexandrov, L B, Fullam, A, Martincorena, I, Dawson, K J, Angelopoulos, N, Samur, M K, Szalat, R, Zamora, J, Tarpey, P, Davies, H, Corradini, P, Anderson, K C, Minvielle, S, Neri, A, Avet-Loiseau, H, Keats, J, Campbell, P J, Munshi, N C, and Bolli, N

Published
2018
Full Text
View/download PDF

27. 14-3-3? binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors

Author

Gu, Y, Xu, K, Torre, C, Samur, M, Barwick, B G, Rupji, M, Arora, J, Neri, P, Kaufman, J, Nooka, A, Bernal-Mizrachi, L, Vertino, P, Sun, S-Y, Chen, J, Munshi, N, Fu, H, Kowalski, J, Boise, L H, and Lonial, S

Abstract

14-3-3 proteins are a family of master regulators of intracellular signaling, yet their impact on proteasome function is unknown. We demonstrate that 14-3-3? binds the 11S proteasome activator, limiting proteasome assembly and cellular capacity for protein degradation. To define the functional impact of 14-3-3? proteasomal binding in myeloma cells, silencing and overexpression experiments are performed. We find that downregulation of 14-3-3? impairs myeloma cell growth and confers resistance to clinically used proteasome inhibitors. In a large cohort of newly diagnosed myeloma patients, elevated expression of 14-3-3? is associated with high risk myeloma genetic subtypes and worse prognosis overall. Our work demonstrates the important role of 14-3-3? in regulating proteasome function, myeloma cell growth and sensitivity to therapeutics, and suggests regulation of 14-3-3? as a new approach in myeloma therapy.

Published
2018
Full Text
View/download PDF

31. Evaluation of the Usability of a Serious Game Aiming to Teach Facial Expressions to Schizophrenic Patients.

Author

ISLEYEN, Filiz, GULKESEN, K. Hakan, CINEMRE, Buket, SAMUR, M. Kemal, ZAYIM, Nese, and SEN KAYA, Semiha

Abstract

In some psychological disorders such as autism and schizophrenia, loss of facial expression recognition skill may complicate patient's daily life. Information technology may help to develop facial expression recognition skill by educational software and games. We designed and developed an interactive webbased educational program with which we performed a usability study before investigating its effectiveness on the schizophrenia patients' ability of emotion perception. The purpose of this study is to describe the usability evaluation for a web-based game set that has been designed to teach facial expressions to schizophrenic patients. The usability study was done at two steps; first, we applied heuristic evaluation and the violations were rated in a scale from most to least severe and the major problems were solved. In the second step, think-aloud method was used and the web site was assessed by five schizophrenic patients. Eight experts participated in the heuristic evaluation, in which a total of 60 violations were identified with a mean severity of 2.77 (range: 0-4). All of the major problems (severity over 2.5) were listed and the usability problems were solved by the development team. After solving the problems, five users with a diagnosis of schizophrenia used the web site with the same scenario. They reported to have experienced minor, but different problems. In conclusion, we suggest that a combination of heuristic evaluation and think-aloud method may be an effective and efficient way for usability evaluations for the serious games that have been designed for special patient groups. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

41. Características clínicas de adultos con Diabetes Mellitus 2 del consultorio del Hospital de Penco-Lirquén, Chile.

Author

de la F. Karin, Noack, Marco, Mendoza E., María, Vergara A., and Natalia, Samur M.

Subjects
DIABETES, METABOLIC disorders, HYPERGLYCEMIA, CARDIOVASCULAR diseases, TYPE 2 diabetes
Abstract

Copyright of Revista ANACEM is the property of Asociacion Nacional Cientifica de Estudiantes de Medicina de Chile and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2012

42. Características clínicas de pacientes ingresados con diagnóstico de insuficiencia cardiaca en un Hospital de la Familia y la Comunidad.

Author

Marco, Mendoza E., de la F. Karin, Noack, Natalia, Samur M., and Marí a, Vergara A.

Subjects
HEART failure, HOSPITAL care, PROGNOSIS, RETROSPECTIVE studies, SCIENTIFIC observation
Abstract

Copyright of Revista ANACEM is the property of Asociacion Nacional Cientifica de Estudiantes de Medicina de Chile and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2012

44. Primary lymphoma of bones.

Author

Bayrakci, Kenan, Yildiz, Yusuf, Saglik, Yener, Altay, Murat, Ögüt, Hamit, Samur, Mustafa, Erekul, Selim, Bayrakci, K, Yildiz, Y, Saglik, Y, Altay, M, Ogüt, H, Samur, M, and Erekul, S

Abstract

Copyright of International Orthopaedics is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2001
Full Text
View/download PDF

45. A new multiple myeloma classification system that correlates to disease stage and prognosis

Author

Hans Erik Johnsen, Julie Støve Bødker, Alexander Schmitz, Steffen Falgreen Larsen, Perez-Andres, M., Samur, M. K., Davies, F., Pawlyn, C., Kaiser, M., Johnson, D., Bertsch, U., Broijl, A., Duin, M., Shah, R., Malene Krag Kjeldsen, Kim Steve Bergkvist, Anders Ellern Bilgrau, Preben Johansen, Tarec Christoffer El-Galaly, Samworth, R., Sonneveld, P., Goldschmidt, H., Morgan, G. J., Orfao, A., Munshi, N., Karen Dybkaer, and Martin Bøgsted

49. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications.

Author

Letouzé E, Moreau P, Munshi N, Samur M, Minvielle S, and Touzeau C

Subjects
Humans, Drug Resistance, Neoplasm, Immunotherapy methods, Tumor Microenvironment immunology, Animals, Multiple Myeloma therapy, Multiple Myeloma immunology, T-Lymphocytes immunology, T-Lymphocytes metabolism, Antibodies, Bispecific therapeutic use, Antibodies, Bispecific pharmacology
Abstract

Abstract: Bispecific T-cell engagers (TCEs) are revolutionizing patient care in multiple myeloma (MM). These monoclonal antibodies, that redirect T cells against cancer cells, are now approved for the treatment of triple-class exposed relapsed/refractory MM (RRMM). They are currently tested in earlier lines of the disease, including in first line. Yet, primary resistance occurs in about one-third of patients with RRMM, and most responders eventually develop acquired resistance. Understanding the mechanisms of resistance to bispecific TCE is thus essential to improve immunotherapies in MM. Here, we review recent studies investigating the clinical and molecular determinants of resistance to bispecific TCE. Resistance can arise from tumor-intrinsic or tumor-extrinsic mechanisms. Tumor-intrinsic resistance involves various alterations leading to the loss of the target antigen, such as chromosome deletions, point mutations, or epigenetic silencing. Loss of major histocompatibility complex (MHC) class I, preventing MHC class I: T-cell receptor (TCR) costimulatory signaling, was also reported. Tumor-extrinsic resistance involves abundant exhausted T-cell clones and several factors generating an immunosuppressive microenvironment. Importantly, some resistance mechanisms impair response to 1 TCE while preserving the efficacy of others. We next discuss the clinical implications of these findings. Monitoring the status of target antigens in tumor cells and their immune environment will be key to select the most appropriate TCE for each patient and to design combination and sequencing strategies for immunotherapy in MM., (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results